Back
ESC Professional Premium Access

Real-world eligibility and cost-effectiveness analysis for empagliflozin in patients with heart failure

Session: Chronic heart failure - Pharmacotherapy
Topic: Pharmacotherapy
Speaker: Doctor E. Kim (Daejeon, KR)
Event: ESC Congress 2022

Congress Presentation

Add to my library

Like

About the speaker

Doctor Eui-Soon Kim

Korea Advanced Institute of Science and Technology, Daejeon (Korea (Republic of))
0 follower

4 more presentations in this session

Dapagliflozin utilization following hospitalization for heart failure: real-world insights from EVOLUTION HF, a multinational, observational study

Speaker: Associate Professor G. Savarese (Stockholm, SE)

Access
Abstract
Slides
Like
Thumbnail

Direct effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial

Speaker: Doctor C. Andersen (Herlev, DK)

Access
Abstract
Slides
Like
Thumbnail

Acute effect of empagliflozin on serum uric acid - a subanalysis of the EMPAG-HF trial (effects of empagliflozin on diuresis and renal function in patients with acute decompensated heart failure)

Speaker: Mr J. Bogoviku (Jena, DE)

Access
Abstract
Slides
Like
Thumbnail

Association of heart rate with heart failure outcomes and the effects of empagliflozin in patients with preserved ejection fraction - EMPEROR-Preserved trial

Speaker: Professor M. Boehm (Homburg, DE)

Access
Abstract
Slides
Like
Thumbnail

Access the full session

Chronic heart failure - Pharmacotherapy

Speakers: Doctor E. Kim, Associate Professor G. Savarese, Doctor C. Andersen, Mr J. Bogoviku, Professor M. Boehm
Access
Like
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources